Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed 16 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma. Dinaciclib may stop the growth of cancer cells by clocking some of the enzymes needed for cell growth.

Timeline

Start: 2009-07
Primary completion: 2011-12
Completion: 2012-12

Publications

Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK; Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15;125(3):443-8. doi: 10.1182/blood-2014-05-573741. Epub 2014 Nov 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dinaciclib	Small molecule	30 mg/m2	Intravenous
Subject	Dinaciclib	Small molecule	40 mg/m2	Intravenous
Subject	Dinaciclib	Small molecule	50 mg/m2	Intravenous

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications